Resverlogix Corp.
  • About
    • Overview
    • Team
    • Partnership Strategy
    • Governance
  • Science & Programs
    • BETonMACE
    • Epigenetics
    • Apabetalone
    • Clinical
    • Publications
  • Investors
    • Financial Reports
    • News
    • Presentations & Events
  • Articles & Media
    • Featured Stories
    • From the Archives
  • Contact
    • General
    • Careers
RVX $0.16 -$0.01

Investors

  1. Home
  2. Investors
  3. News

News

To receive future news releases direct to your inbox, subscribe by emailing ir@resverlogix.com.

Historical news and financial information can also be found at www.sedar.com under the Company’s profile.

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Resverlogix Announces One-Year Extension of Debenture
March 20, 2023
Resverlogix Announces New Research Highlighting Apabetalone’s Potential Benefits in Cardiovascular Disease, Heart Failure, and COVID-19
March 2, 2023
  • Financial Reports
  • News
  • Presentations & Events
Fact Sheet Request Info Presentation
About
  • Overview
  • Team
  • Partnership Strategy
  • Governance
Science & Programs
  • BETonMACE
  • Epigenetics
  • Apabetalone
  • Clinical
  • Publications
Investors
  • Financial Reports
  • News
  • Presentations & Events
Articles & Media
  • Featured Stories
  • From the Archives
Contact
  • General
  • Careers
  • Contact
  • Glossary
  • Sitemap
  • Legal